Does TREMELIMUMAB Cause Malignant neoplasm progression? 68 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 68 reports of Malignant neoplasm progression have been filed in association with TREMELIMUMAB (IMJUDO). This represents 2.9% of all adverse event reports for TREMELIMUMAB.
68
Reports of Malignant neoplasm progression with TREMELIMUMAB
2.9%
of all TREMELIMUMAB reports
22
Deaths
9
Hospitalizations
How Dangerous Is Malignant neoplasm progression From TREMELIMUMAB?
Of the 68 reports, 22 (32.4%) resulted in death, 9 (13.2%) required hospitalization, and 6 (8.8%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TREMELIMUMAB. However, 68 reports have been filed with the FAERS database.
What Other Side Effects Does TREMELIMUMAB Cause?
Pyrexia (178)
Diarrhoea (136)
Death (116)
Colitis (115)
Pneumonitis (87)
Pneumonia (85)
Sepsis (82)
Vomiting (78)
Febrile neutropenia (72)
Abdominal pain (64)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which TREMELIMUMAB Alternatives Have Lower Malignant neoplasm progression Risk?
TREMELIMUMAB vs TREMELIMUMAB\TREMELIMUMAB-ACTL
TREMELIMUMAB vs TRENBOLONE
TREMELIMUMAB vs TREOSULFAN
TREMELIMUMAB vs TREPROSTINIL
TREMELIMUMAB vs TREPROSTINIL DIOLAMINE